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http://dx.doi.org/10.1016/j.cgh.2016.12.034The incidence of esophageal adenocarcinoma (EAC)has risen dramatically during the past 4 decades
in the United States and much of the Western world.1
Most clinical guidelines recommend patients with Bar-
rett’s esophagus (BE) undergo endoscopic surveillance
with tissue biopsy to grade the severity of precursor
lesions and detect curable neoplasia.2 In addition, tech-
niques for endoscopic eradication treatment of BE, such
as endoscopic mucosal resection and radiofrequency
ablation (RFA), have increasingly been used to limit
progression to EAC.3
The National Cancer Institute’s (NCI) Cancer Inter-
vention and Surveillance Modeling Network (CISNET)
includes 3 esophageal cancer modeling groups who have
independently developed population-based models for
the natural history of BE and EAC4; these models have
been validated by calibration to NCI Surveillance Epide-
miology and End Results data and by numerous
comparative modeling exercises.5 The aim of the current
study was to use the CISNET models to perform a
comparative modeling analysis to determine the effec-
tiveness and cost-effectiveness of an RFA-centered
endoscopic eradication treatment strategy for manage-
ment of a population of patients with BE. We sought to
test and assess the impact of multiple strategies using
endoscopic eradication therapy on EAC incidence and
mortality and to estimate the number of surveillance
endoscopies and treatments required to produce poten-
tial clinical benefits. In addition, we performed a cost-
effectiveness analysis to assess the various strategies
from a healthcare utilization perspective. Detailedtechnical profiles of each model are available on the NCI
CISNET website, and details regarding the methods are
available in a downloadable pdf file (Supplementary
Materials).6Methods
In our base case analysis, the simulated cohort was
composed of men born in 1950 with BE diagnosed at
age 60. Patients were tracked for EAC incidence and
mortality until death by any cause or age 100. Endo-
scopic surveillance and eradication therapy were
discontinued after age 80. Risk of progression to can-
cer was dependent on calendar year, birth cohort, age,
and sex. Outcomes for each strategy analyzed included
EAC incidence and mortality, total numbers of sur-
veillance endoscopies and endoscopic eradicative
treatments, numbers of treatments needed to avert one
EAC death (NNT/death), unadjusted and quality-
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endoscopy and treatment, and total costs. The NNT/
death was calculated as the total number of ablative
treatments divided by the number of EAC deaths
averted by a given strategy. Because many patients
require multiple treatments, the total number of
treatments required provides a better estimate of
resource utilization than the number of patients who
required treatment. Treatments included the total
number of endoscopic mucosal resection and RFA
treatments. Incremental results compared the NNT/
death for a given strategy with the next least invasive
strategy by dividing the number of additional treat-
ments by the additional EAC mortality reduction in the
more invasive strategy.
Cost-effectiveness analyses were conducted from a
third-party payer perspective. Quality of life (utility
values) were derived from literature and used to
convert absolute life years of each strategy into
quality-adjusted life years (QALYs). We quantified the
effectiveness of each strategy in terms of QALYs
and associated costs, applying the conventional 3%
discount rate to both. Incremental cost-effectiveness
ratios were calculated between strategies as the ratio
of incremental cost to incremental gain in QALYs.
Comprehensive details of model inputs or parameter
estimates including methods for derivations are avail-
able online.6Results
Table 1 summarizes the 5 strategies for the man-
agement of BE. Figure 1 presents the highlighted
modeling results for the strategies for each of the
3 modeling groups with the end points of EAC incidence
and mortality. The model analysis found that the impact
of the different treatment strategies, measured relativeTable 1. Characteristics of Simulated Interventions on BE Patie
Strategy NDBE patients
Natural history No intervention
Surveillance without RFA
treatment (S strategy)
Surveillance endoscopy
with biopsies every 3 y
BE surveillance with treatment
for HGD only (HGD strategy)
Surveillance endoscopy
with biopsies every 3 y
BE surveillance with treatment
for all dysplasia (LGD strategy)
Surveillance endoscopy
with biopsies
every 3 y
Treatment for all BE patients
(BE strategy)
RFA therapy followed
by surveillancea
NDBE, BE with no dysplasia.
aAll post-treatment surveillance intervals can be found in E-table 5.6to a baseline of surveillance alone, was consistent across
all 3 models. High-grade dysplasia (HGD) treatment
resulted in an average decrease in EAC incidence of
51% (range, 46%–54%) and an EAC mortality reduction
of 44% (range, 39%–49%). In terms of NNT/death, HGD
treatment was the most efficient, with a mean of
44 (range, 30–56). In this strategy, relatively few
treatments were required to achieve a substantial
reduction (range, 39%–49%). In contrast, the incre-
mental NNT/death for low-grade dysplasia (LGD)
compared with HGD treatment was 346 and 166 in the
MGH and ERASMUS/UW models, respectively. The LGD
treatment strategy (simulated by the MGH and ERAS-
MUS/UW models only) resulted in a decrease in EAC
incidence by 63% (range, 58%–67%) and EAC mortality
by 58% (range, 53%–62%). Treating all BE patients at
age 60 decreased the number of EAC cases by 71%
(range, 68%–79%) and the number of EAC deaths by
68% (range, 58%–81%). This strategy was resource
intensive, with NNT/death of 350 (range, 253–518)
compared with HGD treatment alone and an incremen-
tal cost-effectiveness ratio of $182,093–$422,256/QALY,
which is above a $100,000/QALY willingness-to-pay
threshold. Model predictions diverged on the cost-
effectiveness of treatment for LGD. Additional results
of our modeling analyses including unadjusted life ex-
pectancy, costs per strategy, and sensitivity analyses on
key parameter inputs and surveillance assumptions are
available online.6Discussion
In conclusion, our results strongly confirm the cur-
rent guidelines that endorse endoscopic eradication
therapy for patients with HGD.2 Our divergent results for
LGD highlight the need for a better understanding of the
uncertainties surrounding the LGD health state.7 Benefitsnt Cohort
LGD patients HGD patients
No intervention No intervention
Surveillance endoscopy
with biopsies every
6 mo in first year,
thereafter every year
Surveillance endoscopy
with biopsies
every 3 mo
Surveillance endoscopy
with biopsies
every year
RFA therapy followed
by surveillancea
RFA therapy followed
by surveillancea
RFA therapy followed
by surveillancea
RFA therapy followed
by surveillancea
RFA therapy followed
by surveillancea
Figure 1. Upper part of figure shows EAC incidence per 1000 BE patients per model and strategy (no discounting). Lower part
of figure shows EAC deaths per 1000 BE patients. EAC incidence and mortality reductions are shown for endoscopic erad-
icative treatment strategies compared with strategy including only surveillance and no endoscopic eradicative treatment. The
range in model estimates reflects differences in model structures and assumptions on BE prevalence and time to development
of malignancy. NH, natural history; S, Surveillance.
September 2017 Endoscopic Eradication of Barrett’s Esophagus 1473are predicted to be achieved for all BE endoscopic
eradication strategies; however, the efficiency of eradi-
cation is substantially reduced if patients with LGD and
no dysplasia are treated, and substantially more re-
sources are required to avert a cancer death in these
settings. These findings were consistent across all 3
CISNET esophageal cancer models and were robust tosensitivity analyses of RFA efficacy and durability. Our
results add further support for endoscopic eradication
therapy for BE patients with HGD and suggest that
strategies targeting less severe disease will require close
scrutiny for cost-effectiveness. Efficiency of care would
be greatly enhanced through improved methods to
stratify risk of cancer in lesser forms of dysplasia and
1474 Kroep et al Clinical Gastroenterology and Hepatology Vol. 15, No. 9therefore to better identify individuals who would
benefit most from endoscopic therapy.
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